The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes.
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Karl Semaan
No Relationships to Disclose
 
Ze Zhang
No Relationships to Disclose
 
Noa Phillips
No Relationships to Disclose
 
Lexi Grisham
No Relationships to Disclose
 
Rebecca Prather
No Relationships to Disclose
 
Katy Beckermann
Consulting or Advisory Role - Adicet Bio; Alpine Immune Sciences; Aravive; Arcus Biosciences; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Nimbus Therapeutics; Xencor
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Pionyr (Inst)
 
Ulka Vaishampayan
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Janssen Oncology; Merck Serono; Mural; Pfizer; Pfizer/Astellas; Sumitomo Pharma Oncology
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Naomi Haas
Consulting or Advisory Role - Eisai; Merck Sharp & Dohme
 
Hans Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Aveo (Inst); Bristol-Myers Squibb (Inst); Hibercell (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
David McDermott
Consulting or Advisory Role - alkermes; Arcus Biosciences; Bristol-Myers Squibb; Cullinan Oncology; Eisai; EMD Serono; exelixis; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
 
Lauren Wood
No Relationships to Disclose
 
Travis Solley
No Relationships to Disclose
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Toni Choueiri
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; bicycle; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Matthew Freedman
Stock and Other Ownership Interests - Precede Bio
Consulting or Advisory Role - Precede Bio
Patents, Royalties, Other Intellectual Property - A pending patent has been filed for detecting neuroendocrine prostate cancer using DNA methylation
 
Scott Haake
Honoraria - Targeted Oncology
Research Funding - Pionyr
Expert Testimony - Hush Blackwell
 
Sylvan Baca
Employment - Dana Farber Cancer Hospital
Stock and Other Ownership Interests - Precede Bio
Patents, Royalties, Other Intellectual Property - Precede Bio
 
Jacob Berchuck
Stock and Other Ownership Interests - Cityblock Health (I); Genome Medical; Musculo; Oncotect; Precede Bio; TracerDx
Honoraria - Guardant Health
Consulting or Advisory Role - Genome Medical; Guardant Health; Musculo; Oncotect; Precede Bio; TracerDx
Speakers' Bureau - Guardant Health
Research Funding - Guardant Health (Inst); Precede Bio (Inst)
Patents, Royalties, Other Intellectual Property - Institutional patent filed on methods for detecting prostate cancer resistance using cell-free DNA
Travel, Accommodations, Expenses - Guardant Health